Research Topics
| S M StahlSummaryAffiliation: Neuroscience Education Institute Country: USA Publications
| Collaborators
|
Detail Information
Publications
Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortexStephen M Stahl
Neuroscience Education Institute, Carlsbad, CA 92009, USA
J Clin Psychiatry 64:230-1. 2003..Thus, blocking norepinephrine transporters leads to an increase in both dopamine and norepinephrine levels in prefrontal cortex as well as improvement in cognition in attention-deficit/hyperactivity disorder...
Psychotherapy as an epigenetic 'drug': psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugsS M Stahl
Department of Psychiatry, University of California San Diego, San Diego, CA, USA
J Clin Pharm Ther 37:249-53. 2012..The leading notion of how therapeutic effects occur in psychiatric disorders is that they happen when symptoms are reduced by improving the efficiency of information processing in hypothetically malfunctioning brain circuits...
Finding what you are not looking for: strategies for developing novel treatments in psychiatryStephen M Stahl
Department of Psychiatry, University of California San Diego, San Diego, California 92037, USA
NeuroRx 3:3-9. 2006..In many cases, the new indications are the more important therapeutic contributions and the most successful commercial application of a drug. Here we describe this strategy of psychiatric drug development and provide numerous examples...
High-cost use of second-generation antipsychotics under California's Medicaid programStephen M Stahl
Neuroscience Education Institute, 5857 Owens Avenue, Suite 102, Carlsbad, California 92008, USA
Psychiatr Serv 57:127-9. 2006..This study assessed patterns of antipsychotic use to identify uses that are associated with high economic cost but for which there is no documented efficacy...
Differences in mechanism of action between current and future antidepressantsStephen M Stahl
Neuroscience Education Institute, Carlsbad, CA 92009, USA
J Clin Psychiatry 64:13-7. 2003..The introduction of antidepressants with novel mechanisms of action could potentially revolutionize the treatment of depression...
Negative symptoms of schizophrenia: a problem that will not go awayS M Stahl
Department of Psychiatry, University of California, San Diego, CA, USA
Acta Psychiatr Scand 115:4-11. 2007..Although efforts thus far to elucidate a distinct schizophrenia subtype based upon negative symptoms have yielded mixed results, there are nevertheless neurobiological correlates of the negative symptom typology...
Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonismStephen M Stahl
Department of Psychiatry, University of California, San Diego, CA, USA
Int J Neuropsychopharmacol 10:575-8. 2007
Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's diseaseStephen M Stahl
Department of Psychiatry, University of California at San Diego and Neuroscience Education Institute, San Diego, CA 92008, USA
Curr Med Res Opin 20:517-24. 2004..This study examined whether galantamine, an AChEI with nicotinic modulation, is associated with nighttime sleeprelated problems...
Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ERStephen M Stahl
Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
CNS Spectr 12:703-11. 2007..Generalized anxiety disorder (GAD) is a chronic illness with psychic and somatic symptoms that do not respond uniformly in the first weeks of treatment...
Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?Stephen M Stahl
Neuroscience Education Institute, and Department of Psychiatry, University of California, San Diego, CA 92008, USA
Int J Neuropsychopharmacol 7:113-6. 2004
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?S M Stahl
Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, CA 92008, USA
Acta Psychiatr Scand 119:171-9. 2009....
Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trialStephen M Stahl
Neuroscience Education Institute, Carlsbad, CA, USA
J Clin Psychiatry 64:1322-7. 2003..This study evaluated the safety and efficacy of escitalopram in outpatients diagnosed with panic disorder...
The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practiceStephen M Stahl
Department of Psychiatry, University of California San Diego, USA
J Clin Psychiatry 64:6-12. 2003..Efficacy and tolerability data from trials to date indicate that ziprasidone's clinical activity is consistent with its receptor profile...
A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trialStephen M Stahl
Department of Psychiatry, University of California, San Diego, CA 92093 9116 A, USA
J Clin Psychopharmacol 30:425-30. 2010....
Understanding pain in depressionStephen Stahl
Neuroscience Education Institute, Carlsbad, CA 92009, USA
Hum Psychopharmacol 19:S9-S13. 2004..A dysfunction at the level of the serotonergic and noradrenergic neurons can thus affect both the ascending and descending pathways resulting in the psychological and somatic symptoms of depression but also in physical painful symptoms...
Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trialStephen M Stahl
1930 Palomar Point Way, Ste 103, Carlsbad, CA 92008, USA
J Clin Psychiatry 71:616-26. 2010..To evaluate the efficacy, safety, and tolerability of fixed-dose agomelatine 25 and 50 mg/d in the treatment of outpatients with moderate-to-severe major depressive disorder (MDD) compared to placebo...
Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studiesS Stahl
Department of Psychiatry, UCSD, San Diego, CA 92008, USA
J Affect Disord 122:39-45. 2010..Dysphoric mania is a common and often difficult to treat subset of bipolar mania that is associated with significant depressive symptoms...
A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentationS M Stahl
Neuroscience Education Institute, 5857 Owens Avenue Suite 102, Carlsbad, CA 92008, USA
Curr Med Chem 11:313-27. 2004..Existing evidence suggests that the best treatments for schizophrenia and psychosis may be long-term trials of a sequence of atypical antipsychotic monotherapies at therapeutic doses...
Fibromyalgia--pathways and neurotransmittersStephen M Stahl
Department of Psychiatry, University of California, San Diego, CA, USA
Hum Psychopharmacol 24:S11-7. 2009....
Evidence of early onset of antidepressant effect in randomized controlled trialsS M Stahl
Clinical Neuroscience Research Center, San Diego, Calif 92122, USA
J Clin Psychiatry 62:17-23; discussion 37-40. 2001....
Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognitionStephen M Stahl
Neuroscience Education Institute, Carlsbad, Calif 92009, USA
J Clin Psychiatry 64:110-1. 2003..ISSUE: Selective norepinephrine reuptake inhibitors such as atomoxetine increase both dopamine and norepinephrine in frontal cortex and may thereby enhance cognitive functioning in attention-deficit/hyperactivity disorder...
Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depressionStephen M Stahl
The Neuroscience Education Institute, Carlsbad, California 92009, USA
Biol Psychiatry 52:1166-74. 2002..CONCLUSIONS: Venlafaxine was significantly more effective than SSRIs in improving depression, perhaps due to enhancing both serotonin and norepinephrine...
The metabolic syndrome and schizophreniaJ M Meyer
Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA
Acta Psychiatr Scand 119:4-14. 2009....
The 5-HT1A agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT2 blockadeE Seifritz
Department of Psychiatry, UCSD, USA
Neurosci Lett 209:41-4. 1996..The spectral non-REM sleep EEG profile might be used to investigate central 5-HT function in humans...
Risperidone and paroxetine given singly and in combination for bipolar depressionRichard C Shelton
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
J Clin Psychiatry 65:1715-9. 2004..The current study was intended to evaluate the effects of the novel antipsychotic risperidone, the selective serotonin reup-take inhibitor (SSRI) paroxetine, and the combination in patients with bipolar disorder...
Does depression hurt?Stephen M Stahl
Neuroscience Education Institute in Carlsbad, CA 92009, USA
J Clin Psychiatry 63:273-4. 2002..Despite these results, the best treatment of depression currently recognizes the 3 types of symptoms and targets them all for complete remission no matter which drug is used...
Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophreniaDennis H Kim
Arbor Scientia, Carlsbad, California 92008, USA
Neurotherapeutics 6:78-85. 2009..In this article we present a discussion of some of the receptor targets that are currently thought to mediate symptoms of schizophrenia, as well as their possible implications for the design of future multifunctional antipsychotics...
L-methylfolate: a vitamin for your monoaminesStephen M Stahl
Neuroscience Education Institute, 1930 Palomar Point Way, Ste 101, Carlsbad, CA 92009, USA
J Clin Psychiatry 69:1352-3. 2008..Synthesis of the monoamine neurotransmitters serotonin, dopamine, and norepinephrine is regulated by L-methylfolate, a derivate of the vitamin folate...
Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agentStephen M Stahl
Department of Psychiatry, University of California-San Diego, La Jolla, CA, USA
CNS Spectr 12:739-44. 2007
Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channelsStephen M Stahl
Neuroscience Education Institute, Carlsbad, CA 92009, USA
J Clin Psychiatry 65:738-9. 2004..Actions of certain anticonvulsants upon voltage-gated sodium channels may not only explain why they are effective mood stabilizers but may also explain why they could be useful adjuncts to antipsychotics for resistant psychosis...
Emotion processing, the amygdala, and outcome in schizophreniaDarius K Shayegan
Department of Clinical Research, Neuroscience Education Institute, 5857 Owens Ave, Suite 102, Carlsbad, CA 92008, USA
Prog Neuropsychopharmacol Biol Psychiatry 29:840-5. 2005..Here, we review deficits in the processing of emotion in schizophrenia, the role of the amygdala in the context of these deficits, and the functional implications of this relationship upon patient outcome...
SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressantsStephen M Stahl
Department of Psychiatry, University of California, San Diego, San Diego, CA, USA
CNS Spectr 10:732-47. 2005..Duloxetine and milnacipran appear better tolerated and essentially devoid of cardiovascular toxicity...
Atypical antipsychotics: matching receptor profile to individual patient's clinical profileDarius K Shayegan
Neuroscience Education Institute, Carlsbad, CA 92008, USA
CNS Spectr 9:6-14. 2004..However, no two atypical antipsychotics possess the same portfolio of actions upon all of these additional neurotransmitter systems...
Symptoms and circuits, part 3: schizophreniaStephen M Stahl
Neuroscience Education Institute in Carlsbad, CA 92009, USA
J Clin Psychiatry 65:8-9. 2004..Schizophrenia is composed of not only positive symptoms, but also cognitive and affective symptoms that contribute significantly to morbidity. Each of these symptoms may be mediated by a separate and distinct neuronal circuit...
Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trialsStephen M Stahl
Neuroscience Education Institute and Department of Psychiatry, University of California, San Diego, California, USA
J Clin Psychopharmacol 22:388-92. 2002..The incidence of treatment-emergent agitation or anxiety was comparable between treatment groups...
Awakening to the psychopharmacology of sleep and arousal: novel neurotransmitters and wake-promoting drugsStephen M Stahl
Neuroscience Education Institute, Carlsbad, Calif. 92009, USA
J Clin Psychiatry 63:467-8. 2002..Selectively inducing normal wakefulness without stimulating external vigilance may lead to therapeutic benefits not only in sleep disorders but also in cognitive disorders and conditions associated with fatigue...
Antipsychotic polypharmacy: squandering precious resources?Stephen M Stahl
Neuroscience Education Institute, Carlsbad, Calif 92009, USA
J Clin Psychiatry 63:93-4. 2002
Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorderStephen M Stahl
Neuroscience Education Institute, Carlsbad, CA 92009, USA
J Clin Psychiatry 64:6-17. 2003..With this approach, the frequently residual symptoms of sleepiness, fatigue, and executive dysfunction can be targeted with bupropion, atomoxetine, modafinil, atypical antipsychotics, and stimulants...
Human sleep EEG following the 5-HT1A antagonist pindolol: possible disinhibition of raphe neuron activityE Seifritz
Mental Health Clinical Research Center, Department of Psychiatry, University of California at San Diego, USA
Brain Res 759:84-91. 1997....
Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?P F Buckley
Department of Psychiatry, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA
Acta Psychiatr Scand 115:93-100. 2007..Initial enthusiasm that second-generation antipsychotics would prove to be powerful agents to improve negative symptoms has given way to relative pessimism that the effects of current pharmacological treatments are at best modest...
Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromesStephen M Stahl
Neuroscience Education Institute in Carlsbad, CA 92009, USA
J Clin Psychiatry 64:745-6. 2003....
Do dopamine partial agonists have partial efficacy as antipsychotics?Stephen M Stahl
Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
CNS Spectr 13:279-82. 2008
Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the communityStephen M Stahl
Department of Psychiatry, University of California at San Diego and Neuroscience Education Institute, USA
J Clin Psychiatry 64:466-72. 2003..Because sleep quality may be a critical issue for persons with AD and their caregivers, more rigorous evaluation of sleep problems linked to AChE-inhibitor treatment is indicated...
Tailoring treatment of depression for women across the reproductive lifecycle: the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacologyDana D Wise
Arbor Scientia, Carlsbad, CA, USA
CNS Spectr 13:647-62. 2008..To attain optimal outcomes, modern psychopharmacologists must tailor treatment of depression to a woman's reproductive stage of life...
Effectiveness of St John's wort in major depression: a randomized controlled trialR C Shelton
Department of Psychiatry, Vanderbilt University, Nashville Tennessee, USA
JAMA 285:1978-86. 2001..Extracts of St John's wort are widely used to treat depression. Although more than 2 dozen clinical trials have been conducted with St John's wort, most have significant flaws in design and do not enable meaningful interpretation...
At long last, long-lasting psychiatric medications: an overview of controlled-release technologiesStephen M Stahl
Neuroscience Education Institute, Carlsbad, CA 92009, USA
J Clin Psychiatry 64:355-6. 2003
The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disordersStephen M Stahl
Department of Psychiatry, University of California-San Diego, La Jolla, CA, USA
CNS Spectr 13:467-83. 2008
Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamineStephen M Stahl
Neuroscience Education Institute, Carlsbad, California 92009, USA
J Clin Psychiatry 64:4-5. 2003..ISSUE: Since the frontal cortex has a low density of dopamine transporters, dopamine has to be inactivated there by hitching a ride on the norepinephrine transporter of neighboring norepinephrine neurons...
Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agentsStephen M Stahl
Neuroscience Education Institute, Carlsbad, CA 92009, USA
J Clin Psychiatry 63:854-5. 2002..Issue: Both serotonin and GABA powerfully regulate the neuroanatomical circuit that mediates fear in anxiety disorders. This suggests that use of pharmacotherapies acting on both systems may provide synergistic therapeutic actions...
Multifunctional drugs: a novel concept for psychopharmacologyStephen M Stahl
Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
CNS Spectr 14:71-3. 2009..quot; The concept is presented in overview here. Future installments will cover specific drugs in greater depth. Multifunctional drugs include those agents with more than one putative therapeutic mechanism of action...
Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressantsStephen M Stahl
Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
CNS Spectr 13:855-70. 2008..Those with no previous interest in MAOIs may discover in this article a new "secret weapon" to add to their therapeutic armamentarium for patients who fail to respond to the better-known agents...
Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophreniaStephen M Stahl
Department of Psychiatry, University of California-San Diego, La Jolla, CA, USA
CNS Spectr 12:265-8. 2007
Deconstructing psychiatric disorders, part 2: An emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologistStephen M Stahl
Neuroscience Education Institute, 5857 Owens Street, Suite 102, Carlsbad, CA 92009, USA
J Clin Psychiatry 64:1145-6. 2003
Deconstructing psychiatric disorders, Part 1. Genotypes, symptom phenotypes, and endophenotypesStephen M Stahl
Neuroscience Education Institute, 5857 Owens Street, Ste. 102, Carlsbad, CA 92009, USA
J Clin Psychiatry 64:982-3. 2003
Mechanism of action of voltage sensitive sodium channel modulatorsStephen M Stahl
Neuroscience Education Institute in Carlsbad, CA 92009, USA
J Clin Psychiatry 65:894-5. 2004
Symptoms and circuits, part 1: major depressive disorderStephen M Stahl
Neuroscience Education Institute in Carlsbad, CA 92009, USA
J Clin Psychiatry 64:1282-3. 2003..ISSUE: Major depressive disorder comprises multiple symptoms. Each symptom may be mediated by separate and distinct neuronal circuits...
Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptorsStephen M Stahl
Department of Psychiatry, University of California-San Diego, La Jolla, CA, USA
CNS Spectr 12:423-7. 2007
Clinical management of major depressive disorderLaurence Mignon
Neuroscience Education Institute in Carlsbad, CA, USA
CNS Spectr 14:3-6; quiz 7-8. 2009..Adequately managing residual symptoms will hopefully lead to increased remission in these patients. This supplement focuses on the different types of residual symptoms that patients experience and suggests various treatment options...
Norepinephrine and dopamine regulate signals and noise in the prefrontal cortexStephen M Stahl
Neuroscience Education Institute in Carlsbad, California, and the Department of Psychiatry at the University of California San Diego, CA, USA
J Clin Psychiatry 70:617-8. 2009..ISSUE: Norepinephrine and dopamine work in a cooperative yet reciprocal manner to regulate information processing at pyramidal neurons in the prefrontal cortex...
Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology?Stephen M Stahl
Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
CNS Spectr 13:115-8. 2008
Dosing atypical antipsychoticsAndrew Cutler
Department of Psychiatry, University of Florida, Gainesville, FL, USA
CNS Spectr 13:1-16. 2008....
Psychopharmacology of wakefulness: pathways and neurotransmittersStephen M Stahl
Neuroscience Education Institute, Carlsbad, Calif. 92009, USA
J Clin Psychiatry 63:551-2. 2002
The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomitingStephen M Stahl
Neuroscience Education Institute, Carlsbad, CA 92009, USA
J Clin Psychiatry 64:498-9. 2003..It is possible that blocking NK(1) receptors elsewhere in the CNS will lead to therapeutic actions in depression and other stress-related disorders...
Overview of trends in modern psychopharmacologyStephen M Stahl
Neuroscience Education Institute, and Department of Psychiatry, University of California-San Diego, La Jolla, CA, USA
CNS Spectr 12:103-5. 2007
Toward convergence in the medication treatment of bipolar disorder and schizophreniaLeslie Citrome
Department of Psychiatry, New York University School of Medicine, NY, USA
Harv Rev Psychiatry 13:28-42. 2005....
Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action?Stephen M Stahl
Neuroscience Education Institute, 5857 Owens Street, Suite 102, Carlsbad, CA 92009, USA
J Clin Psychiatry 65:149-50. 2004..ISSUE: Anticonvulsants are not a single therapeutic class, but are composed of multiple distinct subclasses with different mechanisms of action, efficacies, and side effects...
Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulatorStephen M Stahl
Neuroscience Education Institute in Carlsbad, CA 92009, USA
J Clin Psychiatry 65:1162-3. 2004..Levetiracetam binds selectively and with high affinity to a synaptic vesicle protein known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release...
Preemptive analgesia: is pain less costly when you pre-pay for it?Stephen M Stahl
Neuroscience Education Institute in Carlsbad, CA 92009, USA
J Clin Psychiatry 65:1591-2. 2004..ISSUE: Early treatment of pain could thwart the development of chronic persistent painful conditions...
Introduction: optimizing wakefulness in patients with fatigue and executive dysfunctionStephen M Stahl
Neuroscience Education Institute, Carlsbad, CA 92009, USA
J Clin Psychiatry 64:3-4. 2003
Antidepressant treatment of psychotic major depression: potential role of the sigma receptorStephen M Stahl
Neuroscience Education Institute, University of California-San Diego, San Diego, CA, USA
CNS Spectr 10:319-23. 2005....
Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistaminesStephen M Stahl
Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
CNS Spectr 13:1027-38. 2008..Selective H1 antagonism is emerging as a novel approach to the treatment of insomnia, without tolerance, weight gain, or the need for the restrictive prescription scheduling required of other hypnotics...
Mirror, mirror on the wall, which enantiomer is fairest of them all?Stephen M Stahl
Neuroscience Education Institute, 5857 Owens Street, Ste 102, Carlsbad, CA 92009, USA
J Clin Psychiatry 63:656-7. 2002..Numerous psychotropic drugs exist as a mixture of 2 mirror-image stereoisomers of each other, each called an enantiomer and the mixture called a racemate. Often the drug can be improved when only 1 of the enantiomers is administered...
Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulatorsStephen M Stahl
Neuroscience Education Institute in Carlsbad, Calif, and the Department of Psychiatry at the University of California San Diego, 92009, USA
J Clin Psychiatry 65:1033-4. 2004..Modulation of VSCCs by certain drugs such as pregabalin and gabapentin via binding to the alpha2delta subunits of VSCCs can lead to anticonvulsant, anxiolytic, and chronic pain-relieving actions...
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channelsStephen M Stahl
Neuroscience Education Institute in Carlsbad, California 92009, USA
J Clin Psychiatry 65:596-7. 2004..ISSUE: Anticonvulsants that act as ligands at alpha(2)delta subunits of voltage-gated calcium channels are proving to be novel treatments for chronic pain...
The psychopharmacology of painful physical symptoms in depressionStephen M Stahl
Neuroscience Education Institute in Carlsbad, Calif 92009, USA
J Clin Psychiatry 63:382-3. 2002
Anticonvulsants as anxiolytics, part 2: Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channelsStephen M Stahl
Neuroscience Education Institute, 5857 Owens Street, Suite 102, Carlsbad, CA 92009, USA
J Clin Psychiatry 65:460-1. 2004
Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABAStephen M Stahl
Neuroscience Education Institute, 5857 Owens Street, Carlsbad, CA 92009, USA
J Clin Psychiatry 65:291-2. 2004
The psychopharmacology of energy and fatigueStephen M Stahl
Neuroscience Education Institute in Carlsbad, Calif 92009, USA
J Clin Psychiatry 63:7-8. 2002..Recent understanding of interactions between monoaminergic neurons may help explain why some antidepressants may be more rapidly energy restoring than others...
The ups and downs of novel antiemetic drugs, part 2: an illustrationStephen M Stahl
Neuroscience Education Institute in Carlsbad, Calif, and the Department of Psychiatry at the University of California San Diego, CA92009, USA
J Clin Psychiatry 64:626-7. 2003....
Drug combinations for bipolar spectrum disorders: evidence-based prescribing or prescribing-based evidence?Stephen M Stahl
Neuroscience Education Institute in Carlsbad, Calif 92009, USA
J Clin Psychiatry 65:1298-9. 2004
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disordersJeanne Stemmelin
Sanofi Aventis, CNS Research, Bagneux, France
Neuropsychopharmacology 33:574-87. 2008..Taken as a whole, these findings indicate that the pharmacological stimulation of beta3 adrenoceptors may represent an innovative approach for the treatment of anxiety and depressive disorders...
Positive findings for negative symptoms of schizophrenia: no longer untreatable?Stephen M Stahl
Acta Psychiatr Scand 114:301-2. 2006
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorderMarcia F T Rupnow
Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ 08560, USA
Curr Med Res Opin 23:2815-22. 2007..The use of adjunctive psychotropics and the costs of polypharmacy in patients randomized to receive risperidone or quetiapine were compared in a placebo-controlled double-blind study conducted in India, Romania, and the United States...
Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorderStephen M Stahl
J Clin Psychiatry 63:756-7. 2002
The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medicationAlan J Gelenberg
University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
J Clin Psychiatry 65:1114-9. 2004..A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo...
Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studiesGeorge I Papakostas
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 69:1287-92. 2008....
Prophylactic antipsychotics: do they keep you from catching schizophrenia?Stephen M Stahl
Neuroscience Education Institute in Carlsbad, Calif 92009, USA
J Clin Psychiatry 65:1445-6. 2004
Brainstorms: symptoms and circuits, part 2: anxiety disordersStephen M Stahl
Neuroscience Education Institute in Carlsbad, Calif. 92009, USA
J Clin Psychiatry 64:1408-9. 2003..ISSUE: Numerous anxiety disorders may have malfunctioning neuronal circuits in common, which may account for the overlapping symptoms and frequent comorbidity of many anxiety disorders with one another...
Is psychopharmacologic "inoculation" effective in preventing posttraumatic stress disorder?Stephen M Stahl
Neuroscience Education Institute in Carlsbad, CA 92099, USA
J Clin Psychiatry 66:5-6. 2005
Can psychopharmacologic treatments that relieve symptoms also prevent disease progression?Stephen M Stahl
Neuroscience Education Institute in Carlsbad, Calif, USA
J Clin Psychiatry 63:961-2. 2002
A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorderEric Hollander
Department, of Psychiatry, Box 1230, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, USA
World J Biol Psychiatry 4:30-4. 2003..Its effectiveness in specific subgroups of OCD patients with co-morbid anxiety disorders or as an augmentation strategy added to SSRIs remains to be determined...
